SkinBioTherapeutics (5KW) Financial Statements

1 Followers

SkinBioTherapeutics Financial Overview

SkinBioTherapeutics's market cap is currently €28.65M. The company's EPS TTM is €-0.0031; its P/E ratio is -52.78; SkinBioTherapeutics is scheduled to report earnings on June 8, 2026, and the estimated EPS forecast is €―. See an overview of income statement, balance sheet, and cash flow financials.

	Jun 24	Jun 23	Jun 22	Jun 21	Jun 20
Income Statement
Total Revenue	£ 4.64M	£ 1.21M	£ 132.06K	£ 74.76K	£ 0.00
Gross Profit	£ 2.71M	£ 683.04K	£ 85.19K	£ 45.34K	£ -5.05K
Operating Income	£ -826.79K	£ -2.90M	£ -3.00M	£ -2.98M	£ -1.49M
EBITDA	£ -196.54K	£ -2.72M	£ -2.96M	£ -2.95M	£ -1.49M
Net Income	£ -696.25K	£ -2.88M	£ -2.84M	£ -2.79M	£ -1.43M
Balance Sheet
Cash & Short-Term Investments	£ 4.78M	£ 800.90K	£ 1.31M	£ 1.80M	£ 4.61M
Total Assets	£ 12.13M	£ 5.22M	£ 2.59M	£ 3.08M	£ 5.73M
Total Debt	£ 993.47K	£ 818.74K	£ 100.65K	£ 127.86K	£ 139.85K
Net Debt	£ -3.79M	£ 17.84K	£ -1.21M	£ -1.68M	£ -4.47M
Total Liabilities	£ 2.71M	£ 2.25M	£ 599.34K	£ 609.61K	£ 519.67K
Stockholders' Equity	£ 9.42M	£ 2.97M	£ 1.99M	£ 2.48M	£ 5.22M
Cash Flow
Free Cash Flow	£ -1.30M	£ -2.92M	£ -2.81M	£ -2.77M	£ -1.67M
Operating Cash Flow	£ -1.30M	£ -2.73M	£ -2.65M	£ -2.67M	£ -1.56M
Investing Cash Flow	£ -1.62M	£ -2.30M	£ -165.28K	£ -96.81K	£ -112.31K
Financing Cash Flow	£ 6.90M	£ 4.51M	£ 2.32M	£ -35.12K	£ 4.12M

Currency in GBP

SkinBioTherapeutics Earnings and Revenue History

Income Statement >

SkinBioTherapeutics Debt to Assets

Balance Sheet >

SkinBioTherapeutics Cash Flow

Cash Flow >

SkinBioTherapeutics Forecast EPS vs Actual EPS

Earnings >